The second-generation version of the VUZE System reportedly offers expanded functionality and incorporation of varied sources of 3D imaging data, including cone-beam CT scans obtained in the OR.
The Food and Drug Administration (FDA) has granted 510(k) clearance for a second-generation update of the VUZE System, which overlays positioning of surgical tools from intraoperative X-rays onto cross-sectional, pre-operative computed tomography (CT) scans.
VUZE Medical, the manufacturer of the VUZE System, emphasized that the new version of the software can be utilized with a larger range of surgical C-arm devices. The company added that the updated VUZE system may incorporate 3D imaging source data from cone-beam CT scans obtained in the operating room as well as pre-operative CT imaging.
The second-generation update of the VUZE system, which overlays positioning of surgical tools from intraoperative X-rays onto cross-sectional, pre-operative computed tomography (CT) scans, has garnered 510(k) clearance from the Food and Drug Administration (FDA). (Images courtesy of VUZE Medical.)
Expanded functionality with the second-generation version of the software also enables surgical planning on compatible standalone laptops, according to VUZE Medical.
“Our second generation significantly extends the applicability of the VUZE System across desired surgical workflows and operating room setups,” said David Tolkowsky, the founder and CEO of VUZE Medical. “In each of those situations, our aim is to preserve the advantages of common X-ray guidance while addressing its shortcomings.”
While noting a current focus of the VUZE System in facilitating minimally invasive thoracolumbar stabilizations, VUZE Medical said it plans to pursue additional clearances for spinal and skeletal interventions.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.